|
|
Article: Novartis files Elidel (pimecrolimus, SDZ ASM 981), its novel treatment for atopic eczema, in the European Union; New cream offers hope for adults and children as young as three months.
- Article from:
- M2 Presswire
- Article date:
- June 18, 2001
CopyrightCOPYRIGHT 2001 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-18 June 2001-NOVARTIS: Novartis files Elidel (pimecrolimus, SDZ ASM 981), its novel treatment for atopic eczema, in the European Union; New cream offers hope for adults and children as young as three months (C)1994-2001 M2 COMMUNICATIONS LTD
RDATE:15062001
Basel -- Novartis announced today that it has filed for marketing approval for Elidel cream (pimecrolimus, SDZ ASM 981) for atopic eczema (also known as atopic dermatitis) in the European Union. The cream can be used with adults and children as young as three months old.
Elidel is the first and only treatment proven to prevent severe flares of atopic eczema and to eliminate or ...